Participants 76 137 5
paclitaxel-pretreated patients with metastatic breast cancer:
Participants 222 519 7
OBJECTIVE A randomized phase II trial was conducted to test whether the addition of gemcitabine to weekly docetaxel could improve the objective response rate and survival outcomes as second-line chemotherapy in patients with metastatic breast cancer who have failed a paclitaxel-containing regimen
